Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial (Q33402747)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial |
scientific article |
Statements
1 reference
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial (English)
1 reference
Didier Frappaz
1 reference
Bjørn Henning Grønberg
1 reference
Christine Marosi
1 reference
Roger Stupp
1 reference
Henrik Schultz
1 reference
Björn Tavelin
1 reference
Benoit Lhermitte
1 reference
Johan Rosell
1 reference
Roger Henriksson
1 reference
Nordic Clinical Brain Tumour Study Group (NCBTSG)
1 reference
8 August 2012
1 reference
1 reference
13
1 reference
916-926
1 reference
Identifiers
1 reference
1 reference